Top Research Chief for India: Merck’s Molnupiravir has ‘Major Safety Concerns’

With 26 research institutes, India’s ICMR or “Indian Council of Medical Research ” represents one of the largest and oldest apex medical research bodies worldwide. Overseeing research in the world’s second most populated nation and, according to some sources, the world’s fifth-largest economy as measured by gross domestic product (GDP), ICMR’s declarations as to the safety and efficacy of various investigational medical products carries considerable weight. Despite India’s drug regulatory body—the Drugs Controller General of India (DCGI) clearing Merck’s molnupiravir as the first antiviral COVID-19 orally administrated therapy, ICMR Chief Balram Bhargava has declared publicly that his group has “major safety concerns” associated with molnupiravir.

In a recent press conference, the ICMR chief declared:

“First of all, the US has approved it based on only 1,433 patients with a three per cent reduction in moderate disease when given in mild cases. However, we have to remember that this drug has major safety concerns.”

“It can cause teratogenicity and mutagenicity and cause cartilage damage and be damaging to the muscles. More importantly, if given to a man or a wom…

Quality journalism costs money to produce. We will be reinvesting the proceeds of these subscriptions into an increasing volume of high quality, independent, unbiased reporting and expert analysis. Our subscription tiers use the ‘honor system’  – please do not abuse it. All tiers of service provide the same level of access to content.  We are grateful for all of you, and we hope you reciprocate.

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

TrialSite Staff

Read Source